[
  {
    "ts": "2026-01-10T18:09:36+00:00",
    "headline": "Why Analysts See The Insulet (PODD) Story Shifting As Omnipod Growth Meets Valuation Questions",
    "summary": "Insulet’s fair value estimate has been held steady at US$377.72 per share, with only fractional tweaks to the underlying inputs such as the discount rate and revenue growth used in the model. This kind of fine tuning fits with recent Street research, where most analysts are still focused on Omnipod execution, type 2 diabetes uptake and the long term growth framework, while a smaller group keeps valuation and sector risks front of mind. Stay tuned to see how you can track these subtle but...",
    "url": "https://finance.yahoo.com/news/why-analysts-see-insulet-podd-180936979.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dc568466-1e5f-3582-908d-918b038a6815",
      "content": {
        "id": "dc568466-1e5f-3582-908d-918b038a6815",
        "contentType": "STORY",
        "title": "Why Analysts See The Insulet (PODD) Story Shifting As Omnipod Growth Meets Valuation Questions",
        "description": "",
        "summary": "Insulet’s fair value estimate has been held steady at US$377.72 per share, with only fractional tweaks to the underlying inputs such as the discount rate and revenue growth used in the model. This kind of fine tuning fits with recent Street research, where most analysts are still focused on Omnipod execution, type 2 diabetes uptake and the long term growth framework, while a smaller group keeps valuation and sector risks front of mind. Stay tuned to see how you can track these subtle but...",
        "pubDate": "2026-01-10T18:09:36Z",
        "displayTime": "2026-01-10T18:09:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qYSQ6AG4c18KIEG8bfQS1g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mH32bjf22B8VXoaGCZudBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/b23fe2923663ce315e2ef7ba313db8b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-insulet-podd-180936979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-analysts-see-insulet-podd-180936979.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PODD"
            },
            {
              "symbol": "TFC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]